International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC

Starting soon

Conditions studied: Locally Advanced or Metastatic Urothelial Cancer, Urothelial Cancer

In brief

The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer. Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.

Key facts

Study ID

NCT07420855

Run by

Aron Research Foundation Ets

People needed

361

Starts

2026-02-01

Expected to finish

2030-12-01

Last updated by the study team

2026-02-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged >18years
• Histologically confirmed diagnosis of la/mUC of upper and/or lower urinary tract or histologically confirmed diagnosis of rare GU tumors.
• Histologically or radiologically confirmed metastatic disease
• Patients treated with first-line EV+P combination

You may not qualify if…

• Patients without histologically confirmed diagnosis of UC
• Patients without histologically or radiologically confirmed la or mUC

Where it is running

• Ospedale di Macerata — Province of Macerata, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.